Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis

NCT01789242 is registered in ClinicalTrials.gov with Criterium, Inc. as lead sponsor.

NCT NCT01789242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01789242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Lead sponsor
Criterium, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2013
Completion date
July 31, 2017
Enrollment
32 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis, systemic light chain amyloidosis